Fenwick & West represented the initial purchasers in Fluidigm Corporation’s (Nasdaq: FLDM) offering of $50 million aggregate principal amount of 5.25% convertible senior notes due 2024 in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Fluidigm also granted the initial purchasers of the notes a 13-day option to purchase up to an additional $5 million aggregate principal amount of the notes.
Fluidigm is an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight. More information about the offering can be obtained from Fluidigm’s announcement.
The Fenwick transaction team included corporate partners David Michaels and Ran Ben-Tzur and associates Ryan Mitteness, Chance Goldberg, Meredith Evancie and Derrick Chapman; and intellectual property partner Antonia Sequeira, licensing attorney Amy Manning and associates Glenn Foulds, Andrea Nichols and Sang Kwon. Corporate partner Amanda Rose also assisted in the transaction.